Organovo and Collaborators Publish Data in Toxicological Sciences Demonstrating Power of 3D Bioprinted Human Liver Tissues in Modeling Drug-Induced Liver Injury Leading to Fibrosis
Using Organovo’s 3D bioprinted human liver tissues, researchers from
“This data set clearly shows that our ExVive Human Liver Tissue can recapitulate key features of drug, chemical and TGF-β1-induced fibrogenesis at the cellular, molecular, and histological levels and can be used to better understand the onset and progression of human liver injury,” said Dr.
“This demonstration of methotrexate-induced fibrosis in our liver model has become a strong driver of customer adoption,” said
Modeling drug-induced liver injury has been challenging because existing preclinical animal models may fail to translate results into humans due to species variations in metabolism, injury response, and ability to repair and regenerate tissue. 2D cell culture models are also used to study liver disease states, but they do not reliably mimic liver structure, function and multicellular architecture. The Company’s 3D bioprinting technology creates tissues that are spatially patterned, three-dimensional, and multicellular. Organovo’s 3D bioprinted human liver tissues are composed of patient-derived parenchymal (hepatocyte) and non-parenchymal (endothelial and hepatic stellate) cell populations and can provide insights into the dynamic and complex intercellular interactions that occur during drug-induced liver injury. Many drugs, such as methotrexate, offer therapeutic benefits that often outweigh toxicity risks. In these cases, the clinical paradigm is focused on measuring and managing toxicity rather than a requirement that the drug be free from any evidence of toxicity. The ExVive platform stands out as an exceptional tool to model and understand tissue-level toxicity, owing to its durable nature and the presence of multiple tissue-specific cell types that are essential in modulating tissue injury, resistance to injury and recovery.
The publication entitled, “Modeling compound-induced fibrogenesis in vitro using three-dimensional bioprinted human liver tissues,” was published online on
About
Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. The Company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic and other partners.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause the Company's actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products and services based on its technology; the expected benefits and efficacy of the Company's products, services and technology; the market acceptance of the Company's products and services; the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies; the Company's ability to successfully complete the contracts and recognize the revenue represented by the contracts included in its previously reported total contract bookings and secure additional contracted collaborative relationships. These and other factors are identified and described in more detail in the Company's filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 9, 2016 and its Quarterly Report on Form 10-Q filed with the
Investor Contact:Steve Kunszabo Organovo Holdings, Inc. +1 (858) 224-1092 skunszabo@organovo.com Press Contact:Jessica Yingling Little Dog Communications +1 (858) 344-8091 jessica@litldog.com